Why the study?
Does a candesartan-based regimen improve electrocardiographic left ventricular hypertrophy more in hypertensive patients with metabolic syndrome compared to those without?
Does a candesartan-based regimen improve electrocardiographic left ventricular hypertrophy more in hypertensive patients with metabolic syndrome compared to those without?
A candesartan-based regimen induces greater regression of electrocardiographic left ventricular hypertrophy in hypertensive patients with metabolic syndrome compared to those without.
Answers are grounded in this paper and cite their sources.
Greater ECG-LVH regression with candesartan in MS; hypothesis-generating and requires RCTs before practice implications.
The authors assessed the effect of an angiotensin receptor blocker (candesartan)-based regimen on electrocardiographic left ventricular hypertrophy (ECG-LVH) in 276 patients with hypertension, including 141 with the metabolic syndrome (MS). Baseline blood pressure (BP) and ECG-LVH parameters did not differ in patients with and without MS. At the study's end, BP had decreased similarly in both groups. At baseline, 26.1% of patients with MS and 24.7% without MS exhibited ECG-LVH by Cornell product (CorP) criteria (P=NS); 26.8% and 17.2%, respectively, by Sokolow-Lyon product (SokP) (P=.01); 11.4%and 11.8% by Cornell voltage (CorV) (P=NS); and 12.4% and 6.5% by Sokolow-Lyon voltage (SokV) (P=.01). At the study's end, in the MS group, prevalence of ECG-LVH was reduced to 19.5% from 26.1% (P=.001), to 8.5% from 11.4% (P=.01), and to 24.4% from 26.8%(P=.03) by CorP, CorV, and SokP, respectively. In patients without MS, only the CorP criterion showed a significant decrease in ECG-LVH prevalence, declining to 20.5% (P=.01). The relative risk reduction of ECG-LVH was higher in patients with MS according to CorV and SokP criteria (P<.01).
No takes yet. Share an insight, caveat, or question.
Escobar et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: